MyFinsight
Home
Blog
About
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$9,493K
Free Cash flow
-$19,905K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Stock-based compensation expense
Accounts payable
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Accounts receivable, prepaid exp...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-21,505
-19,824
-19,795
-14,614
Depreciation and amortization
107
102
102
110
Stock-based compensation expense
2,672
3,198
2,926
2,860
Revaluation of contingent consideration
300
-
400
100
Accounts receivable, prepaid expenses and other assets
1,219
-742
672
-6,810
Accounts payable
842
1,513
3,963
377
Accrued expenses and other liabilities
-72
-3,026
1,251
1,295
Deferred income
-972
-854
-1,306
-715
Net cash used in operating activities
-19,847
-18,149
-13,131
-10,932
Purchases of property and equipment
58
13
24
23
Purchases of marketable securities
8,929
51,669
4,608
5,198
Proceeds from sales and maturities of marketable securities
19,250
20,750
15,001
19,051
Payment of deferred transaction consideration for in-licensed assets
-
-
-
0
Payments of deferred transaction consideration for in-licensed assets
-
-
833
-
Net cash (used in) provided by investing activities
10,263
-30,932
10,369
13,830
Payments of deferred transaction consideration for in-licensed assets
-
-
2,372
3,044
Proceeds from issuance of common stock under the at-the-market sales agreement, net of issuance costs
0
57,880
-
-
Payments of employee withholding taxes related to restricted stock unit award vesting
23
250
162
0
Proceeds from exercise of employee stock options and the issuance of stock
114
151
-
-
Net cash provided by (used in) financing activities
91
57,781
-2,534
-3,044
Net (decrease) increase in cash and cash equivalents
-9,493
8,700
-5,296
-146
Cash and cash equivalents at beginning of period
28,660
19,960
25,256
24,570
Cash and cash equivalents at end of period
19,167
28,660
19,960
25,256
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sales and
maturities of marketable...
$19,250K
(-64.99%↓ Y/Y)
Proceeds from exercise of
employee stock options...
$114K
Net cash (used in)
provided by investing...
$10,263K
(-57.53%↓ Y/Y)
Net cash provided by
(used in) financing...
$91K
(132.04%↑ Y/Y)
Canceled cashflow
$8,987K
Canceled cashflow
$23K
Net (decrease)
increase in cash and cash...
-$9,493K
(-1240.99%↓ Y/Y)
Canceled cashflow
$10,354K
Stock-based compensation
expense
$2,672K
(-59.50%↓ Y/Y)
Accounts payable
$842K
(-79.50%↓ Y/Y)
Revaluation of contingent
consideration
$300K
(-83.33%↓ Y/Y)
Depreciation and
amortization
$107K
(-55.79%↓ Y/Y)
Purchases of marketable
securities
$8,929K
(-70.16%↓ Y/Y)
Purchases of property and
equipment
$58K
(-9.38%↓ Y/Y)
Payments of employee
withholding taxes related to...
$23K
(-91.90%↓ Y/Y)
Net cash used in
operating activities
-$19,847K
(13.90%↑ Y/Y)
Canceled cashflow
$3,921K
Net loss
-$21,505K
(29.52%↑ Y/Y)
Accounts receivable,
prepaid expenses and...
$1,219K
Deferred income
-$972K
(45.85%↑ Y/Y)
Accrued expenses and
other liabilities
-$72K
(99.32%↑ Y/Y)
Buy us a coffee